The AVAnT1A Study – short for “Antiviral Action against Type 1 diabetes Autoimmunity” – examines whether vaccination against COVID-19 at the age of six months can prevent the development of islet autoantibodies in babies at increased genetic risk of developing type 1 diabetes, thus reducing their risk of developing the condition. In addition, the researchers want to monitor in saliva and stool samples which viruses the children had contact with. This allows the researchers to clarify further connections between type 1 diabetes and viral infections in early childhood.
https://www.helmholtz-munich.de/en/idf/studies/avant1a-study